Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

• Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO
• Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company
• The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will lead Lexaria’s financial operations, mainly as it looks to double down on GLP-1 human clinical studies for the 2024 calendar year (https://ibn.fm/qIeLZ).

Nelson delivers over 15 years of corporate finance and operations experience within the life sciences industry. Having worked in key organizations such as Rain Oncology, Inc., a late-stage precision oncology biotech company, Lexaria’s management is confident that his skills will be of tremendous value to the company and its growth. Nelson has also served in various roles at Rigel Pharmaceuticals, Inc., including Vice President Finance. He was also a vital member of the executive team that developed and launched TAVALISSE(R) to treat chronic immune thrombocytopenia.

“Nelson’s deep financial leadership experience will be instrumental to the execution of Lexaria’s long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet needs,” noted Chris Bunka, Lexaria’s CEO.

This appointment follows Lexaria’s recent move to hire a contract research organization for its second GLP-1 human pilot study. The study will explore the company’s patented DehydraTECH(TM) technology for the improved delivery of glucagon-like peptide 1 (“GLP-1”) drugs used to treat type 2 diabetes and weight loss. Nelson will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company.

Nelson is optimistic about joining the company, citing DehydraTECH’s potential and proven track record.

“Lexaria has a significant opportunity in continuing its pursuit as a global innovator in drug delivery platforms as proven by the strong potential of DehydraTECH in GLP-1 and hypertension,” he noted. “I’m excited to join the team and look forward to contributing to the company’s progress in GLP-1 and other areas,” he added.

This appointment affirms Lexaria’s commitment to actualize the roadmap detailed earlier in the year, and its confidence in the direction it has taken to focus on GLP-1 studies.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is powered by IBN